Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a ...

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52^nd ASCO Annual Meeting evaluated the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.

“This year's ASCO meeting continues to evaluate sequential therapy with ABRAXANE plus gemcitabine in the first-line and as a combination partner for investigational agents to treat metastatic pancreatic cancer,” said Michael Pehl, President, Hematology and Oncology for Celgene. “The ABRAXANE plus gemcitabine combination is playing a key part in research designed to advance care for patients in this historically challenging disease. ...

Source : http://me-newswire.net//news/18114/en...